AI Article Synopsis
- Chronic hepatitis C virus (HCV) infection leads to serious liver issues like cirrhosis and cancer, as well as increased mortality rates.
- Many patients (40-70%) experience non-liver-related health problems such as immune disorders and metabolic issues during chronic infection.
- New treatments called Direct-Acting Antivirals are showing positive outcomes, improving or resolving these non-hepatic conditions after successful viral suppression.
Article Abstract
Chronic hepatitis C virus infection is an important cause of liver cirrhosis, hepatocellular carcinoma and death. Furthermore, it is estimated that about 40-70% of patients develop non-hepatic alterations in the course of chronic infection. Such manifestations can be immune-related conditions, lymphoproliferative disorders and metabolic alterations with serious adverse events in the short and long term. The introduction of new Direct-Acting Antivirals has shown promising results, with current evidence indicating an improvement and remission of these conditions after a sustained virological response.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11053783 | PMC |
| http://dx.doi.org/10.3390/pathogens13040339 | DOI Listing |
Publication Analysis
Top Keywords
chronic hepatitis
8
hepatitis virus
8
virus infection
8
direct-acting antivirals
8
infection extrahepatic
4
extrahepatic disease
4
disease impact
4
impact direct-acting
4
antivirals chronic
4
infection liver
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!